These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Researchers looked at the nine people who had vision problems while using the drugs and is one of several that have ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Among patients with type 2 diabetes, use of GLP-1 agonists may increase the risks for adhesive capsulitis and required ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Learn about the financial strain caused by the skyrocketing demand and costs of GLP-1 drugs, and how health plans and providers are struggling to balance it.

SGLT2 inhibitors and GLP-1 agonists also reduced the risk ... s age into account when deciding which medications to prescribe for type 2 diabetes. Although all of the patients in this review ...

Groundbreaking research reveals how common diabetes medications might offer unprecedented protection against heart attacks and strokes in survivors.

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.